Hartmut Onkels
Overview
Explore the profile of Hartmut Onkels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Snelder N, Hoefman S, Garcia-Hernandez A, Onkels H, Larsson T, Bergmann K
J Pharmacokinet Pharmacodyn
. 2020 Sep;
48(1):39-53.
PMID: 32930923
ASP8232 is a novel inhibitor of vascular adhesion protein-1 that was under evaluation for reducing residual albuminuria in patients with diabetic kidney disease. To characterize the pharmacokinetics (PK) of ASP8232...
2.
Hoefman S, Snelder N, van Noort M, Garcia-Hernandez A, Onkels H, Larsson T, et al.
J Pharmacokinet Pharmacodyn
. 2020 Sep;
48(1):21-38.
PMID: 32929612
The vascular adhesion protein-1 (VAP-1) inhibitor ASP8232 reduces albuminuria in patients with type 2 diabetes and chronic kidney disease. A mechanism-based model was developed to quantify the effects of ASP8232...
3.
Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Heeringa M, Mol R, et al.
Clin Pharmacol Drug Dev
. 2016 Apr;
3(3):194-201.
PMID: 27128609
We investigated the effects of ketoconazole on the pharmacokinetics (PK) of the direct clotting factor Xa inhibitor darexaban (YM150) and its main active metabolite darexaban glucuronide (YM-222714) which almost entirely...
4.
Kadokura T, Kashiwa M, Groenendaal D, Heeringa M, Mol R, Verheggen F, et al.
Biopharm Drug Dispos
. 2013 Aug;
34(8):431-41.
PMID: 23929659
Background: Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial thromboembolic disease. This drug is rapidly and extensively metabolized to darexaban...
5.
Kadokura T, Groenendaal D, Heeringa M, Mol R, Verheggen F, Garcia-Hernandez A, et al.
Eur J Drug Metab Pharmacokinet
. 2013 Jun;
39(1):1-9.
PMID: 23754514
To investigate the impact of the direct Factor Xa inhibitor darexaban administered in a modified-release formulation (darexaban-MR) on the pharmacokinetic (PK) profile of digoxin. In this Phase I, randomized, double-blind,...
6.
Hashimoto T, Suzuki K, Kihara Y, Iwatsubo T, Miyashita A, Heeringa M, et al.
Xenobiotica
. 2012 Nov;
43(6):534-47.
PMID: 23167531
1. The absorption, metabolism and excretion of darexaban (YM150), a novel oral direct factor Xa inhibitor, were investigated after a single oral administration of [(14)C]darexaban maleate at a dose of...
7.
Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Heeringa M, Mol R, et al.
Br J Clin Pharmacol
. 2012 May;
75(2):440-9.
PMID: 22642721
Aims: We investigated the effects of rifampicin on the pharmacokinetics (PK) of the direct clotting factor Xa inhibitor darexaban (YM150) and its main active metabolite, darexaban glucuronide (YM-222714), which almost...